Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure
Tóm tắt
Từ khóa
Tài liệu tham khảo
Henry DH, Bowers P, Romano MT, Provenzano R. Epoetin alfa: clinical evolution of a pleiotropic cytokine.Arch Intern Med. 2004; 164: 262–276.
Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin.N Engl J Med. 1989; 321: 158–163.
Sundal E, Kaeser U. Correction of anaemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year’s treatment in a European multicentre study of 150 haemodialysis-dependent patients.Nephrol Dial Transplant. 1989; 4: 979–987.
Roger SD, MacDougall IC, Thuraisingham RC, Raine AE. Erythropoietin in anemia of renal failure in sickle cell disease.N Engl J Med. 1991; 325: 1175–1176.
Abraham PA, Macres MG. Blood pressure in hemodialysis patients during amelioration of anemia with erythropoietin.J Am Soc Nephrol. 1991; 2: 927–936.
Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells.Nature. 1988; 332: 411–415.
Warrens AN, Cassidy MJ, Takahashi K, Ghatei MA, Bloom SR. Endothelin in renal failure.Nephrol Dial Transplant. 1990; 5: 418–422.
Saito Y, Kazuwa N, Shirakami G, et al. Endothelin in patients with chronic renal failure.J Cardiovasc Pharmacol. 1991; 17(suppl 7): S437-S439.
Deray G, Carayon A, Maistre G, et al. Endothelin in chronic renal failure.Nephrol Dial Transplant. 1992; 7: 300–305.
Mortensen LH, Pawloski CM, Kanagy NL, Fink GD. Chronic hypertension produced by infusion of endothelin in rats.Hypertension. 1990; 15: 729–733.
MacDougall IC. An overview of the efficacy and safety of novel erythropoiesis stimulating protein (NESP).Nephrol Dial Transplant. 2001; 16(suppl 3): 14–21.
Smith KJ, Bleyer AJ, Little WC, Sane DC. The cardiovascular effects of erythropoietin.Cardiovasc Res. 2003; 59: 538–548.
Heidenreich S, Rahn KH, Zidek W. Direct vasopressor effect of recombinant human erythropoietin on renal resistance vessels.Kidney Int. 1991; 39: 259–265.
Tojo A, Doumoto M, Oka K, Numabe A, Kimura K, Yagi S. Endothelin-mediated effect of erythropoietin on blood pressure and renal hemodynamics in hypertensive rats.Am J Physiol. 1996; 270: R744-R748.
Eggena P, Willsey P, Jamgotchian N, et al. Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems.Am J Physiol. 1991; 261: E642-E646.
Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Recombinant human erythro-poietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids.Kidney Int. 1996; 50: 1255–1261.
Anagnostou A, Liu Z, Steiner M, et al. Erythropoietin receptor mRNA expression in human endothelial cells.Proc Natl Acad Sci USA. 1994; 91: 3974–3978.
Miyashita K, Tojo A, Kimura K, et al. Blood pressure response to erythropoietin injection in hemodialysis and predialysis patients.Hypertens Res. 2004; 27: 79–84.
Bode-Boger SM, Boger RH, Kuhn M, Radermacher J, Frolich JC. Endothelin release and shift in prostaglandin balance are involved in the modulation of vascular tone by recombinant erythropoietin.J Cardiovasc Pharmacol. 1992; 20(suppl 12): S25-S28.
Liefeldt L, Schmidt-Ott KM, Orzechowski HD, Distler A, Paul M. Transcriptional regulation of endothelin-1 by erythropoietin in endothelial cells.J Cardiovasc Pharmacol. 1998; 31(suppl 1): S464-S466.
Lopez Ongil SL, Saura M, Lamas S, Rodriguez Puyol M, Rodriguez Puyol D. Recombinant human erythropoietin does not regulate the expression of endothelin-1 and constitutive nitric oxide synthase in vascular endothelial cells.Exp Nephrol. 1996; 4: 37–42.
Shimada N, Saka S, Sekizuka K, et al. Increased endothelin:nitric oxide ratio is associated with erythropoietin-induced hypertension in hemodialysis patients.Ren Fail. 2003; 25: 569–578.
Vaziri ND, Zhou XJ, Smith J, Oveisi F, Baldwin K, Purdy RE. In vivo and in vitro pressor effects of erythropoietin in rats.Am J Physiol. 1995; 269: F838-F845.
Moreau C, Lariviere R, Kingma I, Grose JH, Lebel M. Chronic nitric oxide inhibition aggravates hypertension in erythropoietin-treated renal failure rats.Clin Exp Hypertens. 2000; 22: 663–674.